ReviewResearch (Washington, D.C.)2025
Engineering Macrophage via Biomaterial-Mediated Mitochondrial Regulation: Mechanisms and Strategies.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Bioinspired Artificial Bioenergetic Organelles: Design Principles, Nanofabrication and Therapeutic Translation.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies.Journal of translational medicine · 2026Review
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
- Mechanistic insights and challenges in mitochondrial regulation of macrophage polarization and inflammatory responses.Frontiers in physiology · 2026Review
- Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis.Research (Washington, D.C.) · 2026Article
- Integrated transcriptome and single-cell RNA sequencing identifies small GTPase-associated biomarkers in ulcerative colitis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precisely targeting mitochondria to regulate macrophage fate has emerged as a critical therapeutic paradigm for managing inflammation-related pathologies. Mitochondria, while known for producing ATP, have been increasingly recognized for their critical involvement in immune cell differentiation and activation. As key innate immune effectors, macrophages dynamically adapt to microenvironmental cues through metabolic reprogramming and phenotype polarization, processes fundamentally controlled by mitochondrial homeostasis. Organelle-specific therapeutic advances now position mitochondria-targeted strategies as precision interventions with spatiotemporal advantages over conventional approaches. Crucially, these rationally designed systems demonstrate remarkable potential not only to direct macrophage differentiation toward anti-inflammatory phenotypes but also to reprogram the immune microenvironment concurrently, thereby achieving a breakthrough in precision medicine for inflammatory disorders. This review analyzes mitochondrial homeostasis mechanisms in pathophysiology, establishing design principles for targeted therapies. We classify emerging mitochondrial modulation approaches into indirect regulation and direct targeting, evaluating their impacts on macrophage plasticity and therapeutic efficacy. Critical translational challenges are examined, including single-cell-centric regulation, the complexity of mitochondrial interactions in macrophages, and the inefficiency of traditional trial-and-error strategies. The proposed artificial intelligence (AI)-driven methods such as deep learning-based material design, metabolic network modeling, and advanced small-molecule synthesis can accelerate the development of targeted mitochondrial therapies and enhance clinical feasibility. This synthesis aims to accelerate the development of mitochondrially engineered immunotherapies through rational design principles and standardized evaluation protocols.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.